IN8bio is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of gamma-delta (γδ) T cell therapies for cancer treatment. With a focus on cold, low-mutation cancers, IN8bio utilizes genetically modified γδ T cells to address the challenges associated with these types of tumors. As a pioneer in the field, IN8bio is the first company to introduce genetically modified γδ T cells into clinical trials.

Their innovative platform incorporates allogeneic, autologous, and genetically modified approaches to develop novel cell therapies. These therapies are designed to effectively identify and eliminate tumor cells. Currently, IN8bio's lead product candidates, INB-200 and INB-100, are in Phase 1 clinical trials.

INB-200 targets newly diagnosed glioblastoma (GBM), while INB-100 focuses on leukemia patients undergoing hematopoietic bone marrow transplantation. Driven by their DeltEx platform, IN8bio harnesses the power of γδ T cells, which possess both innate and adaptive immune system properties. These cells can distinguish between healthy and diseased tissue, contributing to direct tumor killing, immune cell recruitment, and immune response activation.

IN8bio's mission is to develop next-generation cell therapies that can significantly enhance outcomes for cancer patients. Under the leadership of their founder and CEO, William Ho, and the guidance of their Chief Scientific Officer, Dr. Lawrence Lamb, an esteemed expert in γδ T cell biology and manufacturing, IN8bio is dedicated to making a positive impact in the field of cancer treatment.

For more information about IN8bio's pipeline, technology, and team, visit their website